ArticleAsian journal of pharmaceutical sciences2021
3D printed tacrolimus suppositories for the treatment of ulcerative colitis.
Article in Asian journal of pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 118 citations in OpenAlex.
- Artificial Intelligence Revolution in Pharmaceutical Sciences : Advancements, Clinical Impacts, and Applications.Current pharmaceutical biotechnology · 2026Review
- Therapeutic Precision: Unveiling the Potential of 3D Printing in Drug Delivery, Tissue Engineering, and Regenerative Medicine.3D printing and additive manufacturing · 2025Article
- Review
- 3D-printing of dipyridamole/thermoplastic polyurethane materials for bone regeneration.Drug delivery and translational research · 2025Article
- The Modulation of Cell Plasticity by Budesonide: Beyond the Metabolic and Anti-Inflammatory Actions of Glucocorticoids.Pharmaceutics · 2025Review
- The role of total polysaccharides fromFrontiers in pharmacology · 2025Article
- Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.Infectious disorders drug targets · 2025Review
- 3D-printed Laponite/Alginate hydrogel-based suppositories for versatile drug loading and release.Drug delivery and translational research · 2024Article
- Customizable Self-Microemulsifying Rectal Suppositories by Semisolid Extrusion 3D Printing.Pharmaceutics · 2024Article
- The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Pulchinenoside B4 ameliorates oral ulcers in rats by modulating gut microbiota and metabolites.Applied microbiology and biotechnology · 2024Article
- 3D Printed Personalized Colon-targeted Tablets: A Novel Approach in Ulcerative Colitis Management.Current drug delivery · 2024Review
- A case study on decentralized manufacturing of 3D printed medicines.International journal of pharmaceutics: X · 2023Article
- 3D printed multi-drug-loaded suppositories for acute severe ulcerative colitis.International journal of pharmaceutics: X · 2023Article
- 3D printed infliximab suppositories for rectal biologic delivery.International journal of pharmaceutics: X · 2023Article
- Additive manufacturing technologies with emphasis on stereolithography 3D printing in pharmaceutical and medical applications: A review.International journal of pharmaceutics: X · 2023Article
- A Bibliometric Analysis of 3D Printing in Personalized Medicine Research from 2012 to 2022.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Additive Manufacturing of an Extended-Release Tablet of Tacrolimus.Materials (Basel, Switzerland) · 2023Article
- Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis.Nature communications · 2023Article
- 3D Printing Technology as a Promising Tool to Design Nanomedicine-Based Solid Dosage Forms: Contemporary Research and Future Scope.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is a global health problem, affecting millions of individuals worldwide. As an inflammatory condition localised in the large intestine, rectal delivery of immunosuppressive therapies such as tacrolimus is a promising strategy to maximise drug concentration at the site of action whilst minimising systemic side effects. Here, for the first time, self-supporting 3D-printed tacrolimus suppositories were prepared without the aid of moulds using a pharmaceutical semi-solid extrusion (SSE) 3D printer. The suppositories were printed vertically in three different sizes using combinations of two lipid pharmaceutical excipients (Gelucire 44/14 or Gelucire 48/16) and coconut oil. Although both suppository formulations had the appropriate viscosity characteristics for printing, the Gel 44 formulation required less energy and force for extrusion compared to the Gel 48 system. The Gel 44 disintegrated more rapidly but released tacrolimus more slowly than the Gel 48 suppositories. Although the tacrolimus release profiles were significantly different, both suppository systems released more than 80% drug within 120 min. DSC and XRD analysis was inconclusive in determining the solid-state properties of the drug in the suppositories. In summary, this article reports on the fabrication of 3D printed self-supporting suppositories to deliver personalised doses of a narrow therapeutic index drug, with potential benefits for patients with ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.